[{"orgOrder":0,"company":"Ohara Pharmaceutical","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Glucarpidase","moa":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Ohara Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Ohara Pharmaceutical \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Ohara Pharmaceutical \/ BTG Specialty Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Ohara Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Voraxaze® is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance due to impaired renal function.

                          Brand Name : Megludase

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 28, 2021

                          Lead Product(s) : Glucarpidase

                          Therapeutic Area : Pharmacology/Toxicology

                          Highest Development Status : Approved

                          Sponsor : BTG Specialty Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank